SMAD-oncoprotein interplay: Potential determining factors in targeted therapies

Morikawa, 2016, TGF-beta and the TGF-beta family: context-dependent roles in cell and tissue physiology, Cold Spring Harb. Perspect. Biol., 8, 10.1101/cshperspect.a021873 Derynck, 1985, Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells, Nature, 316, 701, 10.1038/316701a0 Miyazono, 1988, Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization, J. Biol. Chem., 263, 6407, 10.1016/S0021-9258(18)68800-3 Dubois, 1995, Processing of transforming growth factor beta 1 precursor by human furin convertase, J. Biol. Chem., 270, 10618, 10.1074/jbc.270.18.10618 Shi, 2011, Latent TGF-beta structure and activation, Nature, 474, 343, 10.1038/nature10152 Hara, 2015, L(59) TGF-beta LAP degradation products serve as a promising blood biomarker for liver fibrogenesis in mice, Fibrogenesis Tissue Repair, 8, 17, 10.1186/s13069-015-0034-9 Heldin, 2016, Signaling receptors for TGF-beta family members, Cold Spring Harb. Perspect. Biol., 8, 10.1101/cshperspect.a022053 Wieser, 1995, GS domain mutations that constitutively activate T beta R-I, the downstream signaling component in the TGF-beta receptor complex, EMBO J., 14, 2199, 10.1002/j.1460-2075.1995.tb07214.x Tsukazaki, 1998, SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor, Cell, 95, 779, 10.1016/S0092-8674(00)81701-8 Wu, 2000, Structural basis of Smad2 recognition by the Smad anchor for receptor activation, Science, 287, 92, 10.1126/science.287.5450.92 Di Guglielmo, 2003, Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover, Nat. Cell Biol., 5, 410, 10.1038/ncb975 Panopoulou, 2002, Early endosomal regulation of Smad-dependent signaling in endothelial cells, J. Biol. Chem., 277, 18046, 10.1074/jbc.M107983200 Derynck, 2003, Smad-dependent and Smad-independent pathways in TGF-beta family signalling, Nature, 425, 577, 10.1038/nature02006 Macias-Silva, 1996, MADR2 is a substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation and signaling, Cell, 87, 1215, 10.1016/S0092-8674(00)81817-6 Derynck, 2019, Specificity, versatility, and control of TGF-beta family signaling, Sci. Signal., 12, 10.1126/scisignal.aav5183 Wrighton, 2008, To (TGF)beta or not to (TGF)beta: fine-tuning of Smad signaling via post-translational modifications, Cell. Signal., 20, 1579, 10.1016/j.cellsig.2008.02.003 Feng, 2005, Specificity and versatility in tgf-beta signaling through Smads, Annu. Rev. Cell Dev. Biol., 21, 659, 10.1146/annurev.cellbio.21.022404.142018 Inman, 2002, Stoichiometry of active smad-transcription factor complexes on DNA, J. Biol. Chem., 277, 51008, 10.1074/jbc.M208532200 Chacko, 2001, The L3 loop and C-terminal phosphorylation jointly define Smad protein trimerization, Nat. Struct. Biol., 8, 248, 10.1038/84995 Chacko, 2004, Structural basis of heteromeric smad protein assembly in TGF-beta signaling, Mol. Cell, 15, 813, 10.1016/j.molcel.2004.07.016 Lin, 2006, PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling, Cell, 125, 915, 10.1016/j.cell.2006.03.044 Duan, 2006, Protein serine/threonine phosphatase PPM1A dephosphorylates Smad1 in the bone morphogenetic protein signaling pathway, J. Biol. Chem., 281, 36526, 10.1074/jbc.M605169200 Chen, 2015, Nuclear export of Smads by RanBP3L regulates bone morphogenetic protein signaling and mesenchymal stem cell differentiation, Mol. Cell. Biol., 35, 1700, 10.1128/MCB.00121-15 Dai, 2009, Nuclear export of Smad2 and Smad3 by RanBP3 facilitates termination of TGF-beta signaling, Dev. Cell, 16, 345, 10.1016/j.devcel.2009.01.022 Matsuura, 2004, Cyclin-dependent kinases regulate the antiproliferative function of Smads, Nature, 430, 226, 10.1038/nature02650 Alarcon, 2009, Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways, Cell, 139, 757, 10.1016/j.cell.2009.09.035 Guo, 2008, Axin and GSK3- control Smad3 protein stability and modulate TGF- signaling, Genes Dev., 22, 106, 10.1101/gad.1590908 Ebisawa, 2001, Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation, J. Biol. Chem., 276, 12477, 10.1074/jbc.C100008200 Kavsak, 2000, Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation, Mol. Cell, 6, 1365, 10.1016/S1097-2765(00)00134-9 Liu, 2010, Regulation of TGF-beta signalling by protein phosphatases, Biochem. J., 430, 191, 10.1042/BJ20100427 Souchelnytskyi, 1998, Physical and functional interaction of murine and Xenopus Smad7 with bone morphogenetic protein receptors and transforming growth factor-beta receptors, J. Biol. Chem., 273, 25364, 10.1074/jbc.273.39.25364 Hata, 1998, Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor, Genes Dev., 12, 186, 10.1101/gad.12.2.186 Zhang, 2007, Smad7 antagonizes transforming growth factor beta signaling in the nucleus by interfering with functional Smad-DNA complex formation, Mol. Cell. Biol., 27, 4488, 10.1128/MCB.01636-06 Lin, 2003, Smad6 recruits transcription corepressor CtBP to repress bone morphogenetic protein-induced transcription, Mol. Cell. Biol., 23, 9081, 10.1128/MCB.23.24.9081-9093.2003 Yu, 2019, TGF-beta signaling in cell fate control and cancer, Curr. Opin. Cell Biol., 61, 56, 10.1016/j.ceb.2019.07.007 Shi, 1998, Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling, Cell, 94, 585, 10.1016/S0092-8674(00)81600-1 Shi, 2003, Mechanisms of TGF-beta signaling from cell membrane to the nucleus, Cell, 113, 685, 10.1016/S0092-8674(03)00432-X Zawel, 1998, Human Smad3 and Smad4 are sequence-specific transcription activators, Mol. Cell, 1, 611, 10.1016/S1097-2765(00)80061-1 Ross, 2008, How the Smads regulate transcription, Int. J. Biochem. Cell Biol., 40, 383, 10.1016/j.biocel.2007.09.006 Massague, 2012, TGFbeta signalling in context, Nat. Rev. Mol. Cell Biol., 13, 616, 10.1038/nrm3434 Massague, 2008, TGFbeta in cancer, Cell, 134, 215, 10.1016/j.cell.2008.07.001 Chen, 2002, E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression, Cell, 110, 19, 10.1016/S0092-8674(02)00801-2 Feng, 2000, Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-beta, EMBO J., 19, 5178, 10.1093/emboj/19.19.5178 Seoane, 2004, Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation, Cell, 117, 211, 10.1016/S0092-8674(04)00298-3 Thiery, 2009, Epithelial-mesenchymal transitions in development and disease, Cell, 139, 871, 10.1016/j.cell.2009.11.007 Heldin, 2012, Regulation of EMT by TGFbeta in cancer, FEBS Lett., 586, 1959, 10.1016/j.febslet.2012.02.037 Labbe, 2000, Association of Smads with lymphoid enhancer binding factor 1/T cell-specific factor mediates cooperative signaling by the transforming growth factor-beta and wnt pathways, Proc. Natl. Acad. Sci. USA, 97, 8358, 10.1073/pnas.150152697 Lei, 2004, The murine gastrin promoter is synergistically activated by transforming growth factor-beta/Smad and Wnt signaling pathways, J. Biol. Chem., 279, 42492, 10.1074/jbc.M404025200 Zavadil, 2004, Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition, EMBO J., 23, 1155, 10.1038/sj.emboj.7600069 Su, 2020, TGF-beta orchestrates fibrogenic and developmental EMTs via the RAS effector RREB1, Nature, 577, 566, 10.1038/s41586-019-1897-5 Sekimoto, 2007, Reversible Smad-dependent signaling between tumor suppression and oncogenesis, Cancer Res., 67, 5090, 10.1158/0008-5472.CAN-06-4629 Matsuzaki, 2009, Smad2 and Smad3 phosphorylated at both linker and COOH-terminal regions transmit malignant TGF-beta signal in later stages of human colorectal cancer, Cancer Res., 69, 5321, 10.1158/0008-5472.CAN-08-4203 David, 2016, TGF-beta tumor suppression through a lethal EMT, Cell, 164, 1015, 10.1016/j.cell.2016.01.009 Qing, 2000, Structural and functional characterization of the transforming growth factor-beta -induced Smad3/c-Jun transcriptional cooperativity, J. Biol. Chem., 275, 38802, 10.1074/jbc.M004731200 Janknecht, 1998, TGF-beta-stimulated cooperation of smad proteins with the coactivators CBP/p300, Genes Dev., 12, 2114, 10.1101/gad.12.14.2114 Ogryzko, 1996, The transcriptional coactivators p300 and CBP are histone acetyltransferases, Cell, 87, 953, 10.1016/S0092-8674(00)82001-2 Simonsson, 2006, The DNA binding activities of Smad2 and Smad3 are regulated by coactivator-mediated acetylation, J. Biol. Chem., 281, 39870, 10.1074/jbc.M607868200 Xu, 2016, Posttranslational regulation of Smads, Cold Spring Harb. Perspect. Biol., 8, 10.1101/cshperspect.a022087 Lönn, 2010, PARP-1 attenuates Smad-mediated transcription, Mol. Cell, 40, 521, 10.1016/j.molcel.2010.10.029 Massagué, 2008, TGFbeta in cancer, Cell, 134, 215, 10.1016/j.cell.2008.07.001 Levy, 2006, Alterations in components of the TGF-beta superfamily signaling pathways in human cancer, Cytokine Growth Factor Rev., 17, 41, 10.1016/j.cytogfr.2005.09.009 Yook, 2006, A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells, Nat. Cell Biol., 8, 1398, 10.1038/ncb1508 Singha, 2019, Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF-beta from growth suppressor to growth and metastasis promoter through TMEPAI/PMEPA1 in triple negative breast cancer, Genes Cancer, 10, 134, 10.18632/genesandcancer.194 Hoot, 2008, Keratinocyte-specific Smad2 ablation results in increased epithelial-mesenchymal transition during skin cancer formation and progression, J. Clin. Invest., 118, 2722 Labbe, 1998, Smad2 and Smad3 positively and negatively regulate TGF beta-dependent transcription through the forkhead DNA-binding protein FAST2, Mol. Cell, 2, 109, 10.1016/S1097-2765(00)80119-7 Samanta, 2012, Alterations in the Smad pathway in human cancers, Front. Biosci. (Landmark Ed.), 17, 1281, 10.2741/3986 Kretzschmar, 1999, A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras, Genes Dev., 13, 804, 10.1101/gad.13.7.804 Matsuura, 2005, Identification and characterization of ERK MAP kinase phosphorylation sites in Smad3, Biochemistry, 44, 12546, 10.1021/bi050560g Funaba, 2002, Modulation of Smad2-mediated signaling by extracellular signal-regulated kinase, J. Biol. Chem., 277, 41361, 10.1074/jbc.M204597200 Blanchette, 2001, Cross-talk between the p42/p44 MAP kinase and Smad pathways in transforming growth factor beta 1-induced furin gene transactivation, J. Biol. Chem., 276, 33986, 10.1074/jbc.M100093200 Millet, 2009, A negative feedback control of transforming growth factor-beta signaling by glycogen synthase kinase 3-mediated Smad3 linker phosphorylation at Ser-204, J. Biol. Chem., 284, 19808, 10.1074/jbc.M109.016667 Park, 2018, Heme oxygenase-1/carbon monoxide axis suppresses transforming growth factor-beta1-induced growth inhibition by increasing ERK1/2-mediated phosphorylation of Smad3 at Thr-179 in human hepatocellular carcinoma cell lines, Biochem. Biophys. Res. Commun., 498, 609, 10.1016/j.bbrc.2018.03.030 Yoshida, 2005, Transforming growth factor-beta and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury, Am. J. Pathol., 166, 1029, 10.1016/S0002-9440(10)62324-3 Velden, 2011, c-Jun N-terminal kinase 1 promotes transforming growth factor-beta1-induced epithelial-to-mesenchymal transition via control of linker phosphorylation and transcriptional activity of Smad3, Am. J. Respir. Cell Mol. Biol., 44, 571, 10.1165/rcmb.2009-0282OC Remy, 2004, PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3, Nat. Cell Biol., 6, 358, 10.1038/ncb1113 Conery, 2004, Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosis, Nat. Cell Biol., 6, 366, 10.1038/ncb1117 Mayer, 2016, The PI3K/AKT pathway as a target for cancer treatment, Annu. Rev. Med., 67, 11, 10.1146/annurev-med-062913-051343 Chen, 2001, Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation, Cancer Res., 61, 2429 Mancinelli, 2017, Multifaceted roles of GSK-3 in cancer and autophagy-related diseases, Oxid. Med. Cell Longev., 2017, 4629495, 10.1155/2017/4629495 Zhou, 2004, Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition, Nat. Cell Biol., 6, 931, 10.1038/ncb1173 Kang, 2012, CBL enhances breast tumor formation by inhibiting tumor suppressive activity of TGF-beta signaling, Oncogene, 31, 5123, 10.1038/onc.2012.18 Hahn, 1995, Allelotype of pancreatic adenocarcinoma using xenograft enrichment, Cancer Res., 55, 4670 Thiagalingam, 1996, Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers, Nat. Genet., 13, 343, 10.1038/ng0796-343 Yang, 2006, Acute myelogenous leukemia-derived SMAD4 mutations target the protein to ubiquitin-proteasome degradation, Hum. Mutat., 27, 897, 10.1002/humu.20387 Wan, 2005, SCF(beta-TrCP1) controls Smad4 protein stability in pancreatic cancer cells, Am. J. Pathol., 166, 1379, 10.1016/S0002-9440(10)62356-5 Moren, 2000, Functional consequences of tumorigenic missense mutations in the amino-terminal domain of Smad4, Oncogene, 19, 4396, 10.1038/sj.onc.1203798 Liang, 2004, Ubiquitination and proteolysis of cancer-derived Smad4 mutants by SCFSkp2, Mol. Cell. Biol., 24, 7524, 10.1128/MCB.24.17.7524-7537.2004 Demagny, 2016, Point mutations in the tumor suppressor Smad4/DPC4 enhance its phosphorylation by GSK3 and reversibly inactivate TGF-beta signaling, Mol. Cell Oncol., 3, e1025181, 10.1080/23723556.2015.1025181 Demagny, 2014, The tumor suppressor Smad4/DPC4 is regulated by phosphorylations that integrate FGF, Wnt, and TGF-beta signaling, Cell Rep., 9, 688, 10.1016/j.celrep.2014.09.020 Zhang, 2019, ALK phosphorylates SMAD4 on tyrosine to disable TGF-beta tumour suppressor functions, Nat. Cell Biol., 21, 179, 10.1038/s41556-018-0264-3 Janoueix-Lerosey, 2018, The ALK receptor in sympathetic neuron development and neuroblastoma, Cell Tissue Res., 372, 325, 10.1007/s00441-017-2784-8 Hallberg, 2013, Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology, Nat. Rev. Cancer, 13, 685, 10.1038/nrc3580 Jiang, 2017, Targeting BRK-positive breast cancers with small-molecule kinase inhibitors, Cancer Res., 77, 175, 10.1158/0008-5472.CAN-16-1038 Miah, 2019, BRK phosphorylates SMAD4 for proteasomal degradation and inhibits tumor suppressor FRK to control SNAIL, SLUG, and metastatic potential, Sci. Adv., 5, 10.1126/sciadv.aaw3113 Seoane, 2002, Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage, Nature, 419, 729, 10.1038/nature01119 Staller, 2001, Repression of p15INK4b expression by Myc through association with Miz-1, Nat. Cell Biol., 3, 392, 10.1038/35070076 Seoane, 2001, TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b, Nat. Cell Biol., 3, 400, 10.1038/35070086 Feng, 2002, Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-beta-mediated induction of the CDK inhibitor p15(Ink4B), Mol. Cell, 9, 133, 10.1016/S1097-2765(01)00430-0 Tecalco-Cruz, 2018, Transcriptional cofactors Ski and SnoN are major regulators of the TGF-beta/Smad signaling pathway in health and disease, Signal Transduct. Target Ther., 3, 15, 10.1038/s41392-018-0015-8 Stroschein, 1999, Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein, Science, 286, 771, 10.1126/science.286.5440.771 Nicol, 1999, Association of specific DNA binding and transcriptional repression with the transforming and myogenic activities of c-Ski, Cell Growth Differ., 10, 243 Li, 1986, Unique sequence, ski, in Sloan-Kettering avian retroviruses with properties of a new cell-derived oncogene, J. Virol., 57, 1065, 10.1128/JVI.57.3.1065-1072.1986 Xie, 2017, Ski regulates Smads and TAZ signaling to suppress lung cancer progression, Mol. Carcinog., 56, 2178, 10.1002/mc.22661 Javelaud, 2011, Efficient TGF-beta/SMAD signaling in human melanoma cells associated with high c-SKI/SnoN expression, Mol Cancer, 10, 2, 10.1186/1476-4598-10-2 Zhu, 2016, SnoN Antagonizes the Hippo Kinase Complex to Promote TAZ Signaling during Breast Carcinogenesis, Dev. Cell, 37, 399, 10.1016/j.devcel.2016.05.002 Fumagalli, 1993, Expression of the c-ski proto-oncogene in human melanoma cell lines, Melanoma Res., 3, 23, 10.1097/00008390-199304000-00004 Buess, 2004, Amplification of SKI is a prognostic marker in early colorectal cancer, Neoplasia, 6, 207, 10.1593/neo.03442 Wang, 2009, Dual role of Ski in pancreatic cancer cells: tumor-promoting versus metastasis-suppressive function, Carcinogenesis, 30, 1497, 10.1093/carcin/bgp154 Zhu, 2007, Dual role of SnoN in mammalian tumorigenesis, Mol. Cell. Biol., 27, 324, 10.1128/MCB.01394-06 Luo, 1999, The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling, Genes Dev., 13, 2196, 10.1101/gad.13.17.2196 Suzuki, 2004, c-Ski inhibits the TGF-beta signaling pathway through stabilization of inactive Smad complexes on Smad-binding elements, Oncogene, 23, 5068, 10.1038/sj.onc.1207690 Sun, 1999, SnoN and Ski protooncoproteins are rapidly degraded in response to transforming growth factor beta signaling, Proc. Natl. Acad. Sci. USA, 96, 12442, 10.1073/pnas.96.22.12442 Kiyono, 2009, c-Ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in diffuse-type gastric carcinoma, Cancer Sci., 100, 1809, 10.1111/j.1349-7006.2009.01248.x Heider, 2007, Ski promotes tumor growth through abrogation of transforming growth factor-beta signaling in pancreatic cancer, Ann. Surg., 246, 61, 10.1097/SLA.0b013e318070cafa Edmiston, 2005, Inability of transforming growth factor-beta to cause SnoN degradation leads to resistance to transforming growth factor-beta-induced growth arrest in esophageal cancer cells, Cancer Res., 65, 4782, 10.1158/0008-5472.CAN-04-4354 Fernandez-Pol, 1987, Suppression of the EGF-dependent induction of c-myc proto-oncogene expression by transforming growth factor beta in a human breast carcinoma cell line, Biochem. Biophys. Res. Commun., 144, 1197, 10.1016/0006-291X(87)91438-0 Mulder, 1988, Alterations in c-myc expression in relation to maturational status of human colon carcinoma cells, Int. J. Cancer, 42, 64, 10.1002/ijc.2910420113 Ito, 1990, Modulation of c-myc expression by transforming growth factor beta 1 in human hepatoma cell lines, Jpn. J. Cancer Res., 81, 216, 10.1111/j.1349-7006.1990.tb02552.x Pietenpol, 1990, Transforming growth factor beta 1 suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation, Proc. Natl. Acad. Sci. USA, 87, 3758, 10.1073/pnas.87.10.3758 Riggins, 1996, Mad-related genes in the human, Nat. Genet., 13, 347, 10.1038/ng0796-347 Malliri, 1996, Sensitivity to transforming growth factor beta 1-induced growth arrest is common in human squamous cell carcinoma cell lines: c-MYC down-regulation and p21waf1 induction are important early events, Cell Growth Differ., 7, 1291 Warner, 1999, Myc downregulation by transforming growth factor beta required for activation of the p15(Ink4b) G(1) arrest pathway, Mol. Cell. Biol., 19, 5913, 10.1128/MCB.19.9.5913 Wu, 2003, Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter, Oncogene, 22, 351, 10.1038/sj.onc.1206145 Gartel, 2001, Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3, Proc Natl Acad Sci U S A, 98, 4510, 10.1073/pnas.081074898 Frederick, 2004, Transforming growth factor beta-mediated transcriptional repression of c-myc is dependent on direct binding of Smad3 to a novel repressive Smad binding element, Mol. Cell. Biol., 24, 2546, 10.1128/MCB.24.6.2546-2559.2004 Kim, 2014, The Smad7-Skp2 complex orchestrates Myc stability, impacting on the cytostatic effect of TGF-beta, J. Cell Sci., 127, 411, 10.1242/jcs.136028 Singh, 2010, Sequential activation of NFAT and c-Myc transcription factors mediates the TGF-beta switch from a suppressor to a promoter of cancer cell proliferation, J. Biol. Chem., 285, 27241, 10.1074/jbc.M110.100438 Koenig, 2010, NFAT-induced histone acetylation relay switch promotes c-Myc-dependent growth in pancreatic cancer cells, Gastroenterology, 138, 10.1053/j.gastro.2009.10.045 Stamos, 2013, The beta-catenin destruction complex, Cold Spring Harb. Perspect. Biol., 5, a007898, 10.1101/cshperspect.a007898 Nusse, 2017, Wnt/beta-catenin signaling, disease, and emerging therapeutic modalities, Cell, 169, 985, 10.1016/j.cell.2017.05.016 Wiese, 2018, Wnt signalling: conquering complexity, Development, 145, 12, 10.1242/dev.165902 Bae, 2016, Transforming growth factor beta1 enhances stemness of head and neck squamous cell carcinoma cells through activation of Wnt signaling, Oncol. Lett., 12, 5315, 10.3892/ol.2016.5336 Roarty, 2009, Loss of TGF-beta or Wnt5a results in an increase in Wnt/beta-catenin activity and redirects mammary tumour phenotype, Breast Cancer Res., 11, R19, 10.1186/bcr2244 Hussein, 2003, Smad4 and beta-catenin co-activators functionally interact with lymphoid-enhancing factor to regulate graded expression of Msx2, J. Biol. Chem., 278, 48805, 10.1074/jbc.M305472200 Chakladar, 2005, Synergistic activation of the murine gastrin promoter by oncogenic Ras and beta-catenin involves SMAD recruitment, Biochem. Biophys. Res. Commun., 336, 190, 10.1016/j.bbrc.2005.08.061 Tian, 2013, Association of beta-catenin with P-Smad3 but not LEF-1 dissociates in vitro profibrotic from anti-inflammatory effects of TGF-beta1, J. Cell Sci., 126, 67, 10.1242/jcs.103036 Zhou, 2012, Interactions between beta-catenin and transforming growth factor-beta signaling pathways mediate epithelial-mesenchymal transition and are dependent on the transcriptional co-activator cAMP-response element-binding protein (CREB)-binding protein (CBP), J. Biol. Chem., 287, 7026, 10.1074/jbc.M111.276311 Mitani, 1994, Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia, EMBO J., 13, 504, 10.1002/j.1460-2075.1994.tb06288.x Queisser, 2017, Ecotropic viral integration site 1, a novel oncogene in prostate cancer, Oncogene, 36, 1573, 10.1038/onc.2016.325 Zhang, 2020, Downregulation of EVI1 expression inhibits cell proliferation and induces apoptosis in hilar cholangiocarcinoma via the PTEN/AKT signalling pathway, J. Cancer, 11, 1412, 10.7150/jca.31903 Kurokawa, 1998, The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells, Blood, 92, 4003, 10.1182/blood.V92.11.4003 Deng, 2013, Overexpression of Evi-1 oncoprotein represses TGF-beta signaling in colorectal cancer, Mol. Carcinog., 52, 255, 10.1002/mc.21852 Kurokawa, 1998, The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3, Nature, 394, 92, 10.1038/27945 Izutsu, 2001, The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling, Blood, 97, 2815, 10.1182/blood.V97.9.2815 LaFoya, 2016, Notch: a multi-functional integrating system of microenvironmental signals, Dev. Biol., 418, 227, 10.1016/j.ydbio.2016.08.023 Artavanis-Tsakonas, 1999, Notch signaling: cell fate control and signal integration in development, Science, 284, 770, 10.1126/science.284.5415.770 Sun, 2005, Notch4 intracellular domain binding to Smad3 and inhibition of the TGF-beta signaling, Oncogene, 24, 5365, 10.1038/sj.onc.1208528 Masuda, 2005, Notch1 oncoprotein antagonizes TGF-beta/Smad-mediated cell growth suppression via sequestration of coactivator p300, Cancer Sci., 96, 274, 10.1111/j.1349-7006.2005.00048.x Li, 2011, Endothelial Smad4 maintains cerebrovascular integrity by activating N-cadherin through cooperation with Notch, Dev. Cell, 20, 291, 10.1016/j.devcel.2011.01.011 Blokzijl, 2003, Cross-talk between the Notch and TGF-beta signaling pathways mediated by interaction of the Notch intracellular domain with Smad3, J. Cell Biol., 163, 723, 10.1083/jcb.200305112 Liu, 2014, Notch3 is important for TGF-beta-induced epithelial-mesenchymal transition in non-small cell lung cancer bone metastasis by regulating ZEB-1, Cancer Gene Ther., 21, 364, 10.1038/cgt.2014.39 Zhou, 2016, Notch and TGFbeta form a positive regulatory loop and regulate EMT in epithelial ovarian cancer cells, Cell. Signal., 28, 838, 10.1016/j.cellsig.2016.03.016 Rao, 2003, The intracellular form of notch blocks transforming growth factor beta-mediated growth arrest in Mv1Lu epithelial cells, Mol. Cell. Biol., 23, 6694, 10.1128/MCB.23.18.6694-6701.2003 Wang, 2008, BCL6 represses Smad signaling in transforming growth factor-beta resistance, Cancer Res., 68, 783, 10.1158/0008-5472.CAN-07-0008 Ni, 2019, Bcl6 suppresses cardiac fibroblast activation and function via directly binding to Smad4, Curr Med Sci, 39, 534, 10.1007/s11596-019-2070-y Yoon, 2015, Phosphorylation status determines the opposing functions of Smad2/Smad3 as STAT3 cofactors in TH17 differentiation, Nat. Commun., 6, 7600, 10.1038/ncomms8600 Wang, 2016, STAT3 selectively interacts with Smad3 to antagonize TGF-beta signalling, Oncogene, 35, 4422, 10.1038/onc.2016.145 Pessah, 2002, c-Jun associates with the oncoprotein Ski and suppresses Smad2 transcriptional activity, J. Biol. Chem., 277, 29094, 10.1074/jbc.M202831200 Pessah, 2001, c-Jun interacts with the corepressor TG-interacting factor (TGIF) to suppress Smad2 transcriptional activity, Proc. Natl. Acad. Sci. USA, 98, 6198, 10.1073/pnas.101579798 Zhang, 1998, Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription, Nature, 394, 909, 10.1038/29814 Jiang, 2020, Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion, Gut, 69, 122, 10.1136/gutjnl-2018-317424 Liberati, 1999, Smads bind directly to the Jun family of AP-1 transcription factors, Proc Natl Acad Sci U S A, 96, 4844, 10.1073/pnas.96.9.4844 Sundqvist, 2020, TGFbeta and EGF signaling orchestrates the AP-1- and p63 transcriptional regulation of breast cancer invasiveness, Oncogene, 39, 4436, 10.1038/s41388-020-1299-z Lee, 2007, TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA, EMBO J., 26, 3957, 10.1038/sj.emboj.7601818 Fritsche-Guenther, 2011, Strong negative feedback from Erk to Raf confers robustness to MAPK signalling, Mol. Syst. Biol., 7, 489, 10.1038/msb.2011.27 Eblen, 2004, Mitogen-activated protein kinase feedback phosphorylation regulates MEK1 complex formation and activation during cellular adhesion, Mol. Cell. Biol., 24, 2308, 10.1128/MCB.24.6.2308-2317.2004 Rozakis-Adcock, 1995, MAP kinase phosphorylation of mSos1 promotes dissociation of mSos1-Shc and mSos1-EGF receptor complexes, Oncogene, 11, 1417 Ishii, 2013, Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity, Cancer Res., 73, 4050, 10.1158/0008-5472.CAN-12-3937 Nazarian, 2010, Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation, Nature, 468, 973, 10.1038/nature09626 Sun, 2014, Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma, Nature, 508, 118, 10.1038/nature13121 Song, 2019, Targeting FOXA1-mediated repression of TGF-beta signaling suppresses castration-resistant prostate cancer progression, J. Clin. Invest, 129, 569, 10.1172/JCI122367 Fabregat, 2014, TGF-beta signaling in cancer treatment, Curr. Pharm. Des., 20, 2934, 10.2174/13816128113199990591 Colak, 2017, Targeting TGF-beta Signaling in Cancer, Trends Cancer, 3, 56, 10.1016/j.trecan.2016.11.008 Vijayaraghavan, 2018, Inhibiting CDK in cancer therapy: current evidence and future directions, Target Oncol., 13, 21, 10.1007/s11523-017-0541-2 Sim, 2019, c-Met activation leads to the establishment of a TGFbeta-receptor regulatory network in bladder cancer progression, Nat. Commun., 10, 4349, 10.1038/s41467-019-12241-2 Wan, 2007, Regulatory T cells, transforming growth factor-beta, and immune suppression, Proc. Am. Thorac. Soc., 4, 271, 10.1513/pats.200701-020AW Thomas, 2005, TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance, Cancer Cell, 8, 369, 10.1016/j.ccr.2005.10.012 Tauriello, 2018, TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis, Nature, 554, 538, 10.1038/nature25492 Mariathasan, 2018, TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells, Nature, 554, 544, 10.1038/nature25501 Kloss, 2018, Dominant-negative TGF-beta receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication, Mol. Ther., 26, 1855, 10.1016/j.ymthe.2018.05.003 Tang, 2020, TGF-beta inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors, JCI Insight, 5, 10.1172/jci.insight.133977 Ravi, 2018, Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFbeta enhance the efficacy of cancer immunotherapy, Nat. Commun., 9, 741, 10.1038/s41467-017-02696-6 Lind, 2020, Dual targeting of TGF-beta and PD-L1 via a bifunctional anti-PD-L1/TGF-betaRII agent: status of preclinical and clinical advances, J. Immuno Ther. Cancer, 8 Paz-Ares, 2020, Bintrafusp Alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in second-line treatment of patients with NSCLC: results from an expansion cohort of a phase 1 trial, J. Thorac. Oncol., 10.1016/j.jtho.2020.03.003 Strauss, 2018, Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFbeta, in advanced solid tumors, Clin. Cancer Res., 24, 1287, 10.1158/1078-0432.CCR-17-2653 Yoo, 2020, Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer, J. Immuno. Ther. Cancer, 8 Doi, 2020, Phase I study of the bifunctional fusion protein bintrafusp alfa in asian patients with advanced solid tumors, including a hepatocellular carcinoma safety-assessment, Cohort, Oncologist, 10.1634/theoncologist.2020-0249 Groeneveldt, 2020, Immunotherapeutic potential of TGF-beta inhibition and oncolytic viruses, Trends Immunol., 41, 406, 10.1016/j.it.2020.03.003 Harrington, 2019, Optimizing oncolytic virotherapy in cancer treatment, Nat. Rev. Drug Discov., 18, 689, 10.1038/s41573-019-0029-0 Twumasi-Boateng, 2018, Oncolytic viruses as engineering platforms for combination immunotherapy, Nat. Rev. Cancer, 18, 419, 10.1038/s41568-018-0009-4 Gujar, 2019, SnapShot: cancer immunotherapy with oncolytic viruses, Cell, 176, 10.1016/j.cell.2019.01.051 Hu, 2011, Oncolytic adenovirus expressing soluble TGFbeta receptor II-Fc-mediated inhibition of established bone metastases: a safe and effective systemic therapeutic approach for breast cancer, Mol. Ther., 19, 1609, 10.1038/mt.2011.114 Yang, 2019, An oncolytic adenovirus targeting transforming growth factor beta inhibits protumorigenic signals and produces immune activation: a novel approach to enhance anti-PD-1 and anti-CTLA-4 therapy, Hum. Gene Ther., 30, 1117, 10.1089/hum.2019.059 Esaki, 2017, Blockade of transforming growth factor-beta signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models, Int. J. Cancer, 141, 2348, 10.1002/ijc.30929 Hutzen, 2017, TGF-beta inhibition improves oncolytic herpes viroimmunotherapy in murine models of rhabdomyosarcoma, Mol. Ther. Oncolytics, 7, 17, 10.1016/j.omto.2017.09.001